• ÓÀººÕòÔÆ¶¥¼¯ÍÅ-Ñо¿ÏÔʾÈûĪÀûµ¥¿¹²»Äܼõ»ºÔçÆÚ°¢¶û×Ⱥ£Ä¬²¡µÄ½øÕ¹

    2025-10-02 19:40:48

    Ñо¿ÏÔʾÈûĪÀûµ¥¿¹²»¿Ë²»¼°»º½â³õÆÚ°¢¶û×Ⱥ£Ä¬²¡µÄ½øÕ¹

    ÈÕÆÚ£º2022-07-17 À´Àú£º±¾Õ¾ ¹©¸å£ºÒ½Ò©ÉúÎï¼¼ÄÜ´¦ ×÷ÕߣºÖÎÀíÔ± ÖÖ±ð£ºÒëÎÄ

    ΢¹ÜÏà¸ÉÂѰף¨tauÂѰף©¶Ñ»ýÐγɵÄÉñ¾­ÏËά²ø½áÊǰ¢¶û´Äº£Ä¬²¡£¨AD£©µÄ¾«Éñ²¡ÀíÑ§ÌØÐÔÖ®Ò»£¬²¢ÓëÁÙ´²ÑϾþˮƽÏà¸É¡£ÒÔtauÂѰ×Ϊ°ÐµãµÄµ¥¿Ë¡¿¹Ìå¿É·ñ»º½â»òÕßÖÆÖ¹²¡ÀíÐÔtauµÄÓÀººÕòÔÆ¶¥¼¯ÍÅ-À©É¢»òÕß´¢Ðî»ýÀÛ²¢¸ÄÉÆADµÄ½øÕ¹Éв»³ÉÖª¡£½üÈÕ£¬À´×ÔÃÀ¹ú¡¢Australia¡¢ºÉÀ¼¼°ÈðÊ¿µÄÑо¿ÍŶÓÓÚ¡¶JAMA Neurology¡·ÔÓÖ¾·¢±íÁËÌâΪ¡°Safety and Efficacy of Semorinemab in Individuals With Prodromal toMild Alzheimer Disease¡±µÄÎÄÕ£¬Õë¶ÔÓÚtauÂѰ׵ÄÈûĪÀûµ¥¿¹¾ß±¸ÓÅÁ¼µÄ°²È«ÐÔ£¬µ«²»¿Ë²»¼°»º½â³õÆÚADµÄ½øÕ¹¡£ Ñо¿Õß¾­Óɹý³ÌÁÙ´²Ëæ»ú˫ä±ÈÕÕʵÑ飬ÄÉÈë457Ãû»¼ÓгõÆÚ°¢¶û´Äº£Ä¬²¡µÄÊÜÊÔÕߣ¬ËùÓл¼ÕߵļòÃ÷ÖÇÄÜÁ¿±íÆÀ·ÖΪ20-30·Ö£¬ÇÒ¾ù¾­Óɹý³ÌÕýµç×Ó·¢Éä¶Ï²ãɨÃè»òÕßÄÔ¼¹ÒºÖ¤Ã÷´æÓÚ¦Â-µí·ÛÑùÂѰײ¡ÀíÑ§ÌØÐÔ¡£ÓÚΪÆÚ73ÖܵÄÑо¿Ê±ÆÚ£¬ÈûĪÀûµ¥¿¹Ò½ÖÎ×éµÄÁÙ´²³Õ´ôÆÀ·ÖÔö¼ÓˮƽÓëο½å¼Á×é¿¿½ü£¬ÇÒÁ½×黼Õß²»Á¼·´Ó³µÄ·¢ÉúÂÊûÓÐͳ¼ÆÑ§²îÒì¡£ÌáÐÑÕë¶ÔÓÚtauÂѰ׵ÄÈûĪÀûµ¥¿¹²¢ÎÞ»º½â³õÆÚADµÄÁÙ´²½øÕ¹£¬µ«ÏÔʾ³öÓÅÁ¼µÄ°²È«ÐÔ¡£ ×ÛÉÏ£¬Ñо¿ÕßÈÏΪ£¬ÈÔÐèÒª¶ÔÓÚtauÂѰ׿¹Ìå¾ÙÐиü¶àµÄÑо¿£¬ÒÔÈ·¶¨ÕâÀàÒ½ÖÎÒªÁìµÄÁÙ´²Ð§ÄÜ¡£ ÂÛÎÄÁ´½Ó£ºhttps://jamanetwork.com/journals/jamaneurology/fullarticle/2793069 ×¢£º´ËÑо¿½á¹ûÕª×Ô¡¶JAMA Neurology¡·ÔÓÖ¾£¬ÎÄÕÂÄÚÈݲ»´ú±í±¾ÍøÕ¾²»Ñŵ㼰̬¶È£¬½ö¹©²Î¿¼¡£-ÓÀººÕòÔÆ¶¥¼¯ÍÅ-